Press release17.03.2025, 12.05BioStock: Last trading day for Abliva - the company leaves Nasdaq Stockholm
Regulatory press release03.03.2025, 13.10Delisting of the shares of Abliva: last day of trading 17 March 2025
Regulatory press release25.02.2025, 09.50Abliva applies for delisting and will convene an extraordinary general meeting
Regulatory press release15.12.2024, 20.00Statement by the Board of Directors of Abliva regarding the public cash offer from Pharming
Press release09.12.2024, 08.32Abliva Announces Publication of Results from Phase 1a/b Study of KL1333 in the Scientific Journal Brain
Press release16.09.2024, 08.30Join Abliva for World Mitochondrial Disease Week 2024, September 16 – 22
Press release26.08.2024, 08.46BioStock: Abliva's CEO - We are the leading programme in mitochondrial disease
Regulatory press release19.07.2024, 08.30Positive interim analysis in Abliva's FALCON study triggers convertible loan conversion
Regulatory press release18.07.2024, 22.22Abliva Announces Positive Interim Analysis of the FALCON Study for KL1333 in Primary Mitochondrial Disease